Brief Title: Familial and Atypical Urothelial Cancer Registry

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Determine whether single nucleotide polymorphisms in regions discovered from whole genome scans, such as 8q24 & chromosome 3, & candidate genes, include NAT2 & GSTM1, prev found to be assoc with bladder ca risk, are assoc with UC in this study population

Primary Outcome 1 - Timeframe: 2 years

CONDITION

• Urothelial Cancer
• Renal Pelvis Cancer
• Ureter Cancer
• Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
Urothelial Cancer Cases
Must be ≥ 18 years of age AND

- Must have a diagnosis of urothelial cancer AND

- Must be an English-speaker
Non-Cancer Control Group
Must be ≥ 18 years of age AND

- Must not have cancer or a personal history of cancer, with the exception of skin cancer. AND

- Must not be a blood relative of cases AND

- Must not be a blood relative of another control AND

- Must be an English-speaker
Family Member Control Group:
In select kindreds with a high prevalence of bladder cancer and/or very early onset bladder cancer, first- and second-degree family members of probands may be contacted by the MSKCC study team and invited to complete the questionnaire and submit a saliva sample.
Must be ≥ 18 years of age AND

- Must be a blood relative of a case participant AND

- Must be an English-speaker
Exclusion Criteria:
Have any condition, which in the opinion of the primary MSKCC clinician or investigators precludes their ability to provide informed consent.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: Accepts Healthy Volunteers

OFFICIAL INFORMATION

Name: Dean Bajorin, MD

Role: Principal Investigator

Affiliation: Memorial Sloan Kettering Cancer Center

Overall Contact

Name: Dean Bajorin, MD

Phone: 646-422-4333, 646-735-8118

Email: N/A

LOCATION